Drug Interaction Potentiation Clinical Trial
Official title:
The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1、CYP3A4、CYP3A5、PORGenetic Polymorphism on the Two Drugs
The purpose of this study is to understand the effects of everolimus on tacrolimus pharmacokinetics (pk) in patients receiving de novo kidney transplants.
Multidrug immunosuppression regimens have synergistic effects which allow the use of lower
doses of individual agents. These regimens generally include calcineurin inhibitors (CNIs:
cyclosporine or tacrolimus), mammalian target of rapamycin (mTOR) inhibitors (everolimus or
sirolimus), and corticosteroids. CNIs and mTOR inhibitors are substrates for cytochrome P450
3A4 (CYP3A4) and P-glycoprotein (P-gp); in addition, cyclosporine is a inhibitor of CYP3A4
and P-gp. Therefore, concomitant administration of those drugs may alter their serum levels.
It is remained to be evaluated whether the pharmacokinetics or clinical efficacy of
tacrolimus will be affected when the regimens contain everolimus in clinical practice and the
effect of ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism on the two Drugs. Mycophenolate
mofetil (MMF) has no effect on pharmacokinetics of tacrolimus; therefore, MMF is used as a
control to understand the effects of everolimus on pharmacokinetics of tacrolimus in patients
receiving de novo kidney transplants. The effect of ABCB1、CYP3A4、CYP3A5、POR genetic
polymorphism on the two Drugs was also assessed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03789032 -
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
|
Phase 1 | |
| Completed |
NCT03706222 -
Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
|
||
| Completed |
NCT02191358 -
YouScript IMPACT Registry
|
N/A | |
| Completed |
NCT02485028 -
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg
|
Phase 1 | |
| Completed |
NCT01896557 -
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
|
Phase 4 | |
| Completed |
NCT03011463 -
Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1
|
Phase 1 | |
| Completed |
NCT02485041 -
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg
|
Phase 1 | |
| Completed |
NCT01477424 -
A Drug-Drug Interaction Study of Warfarin and PA21
|
Phase 1 | |
| Completed |
NCT01477411 -
A Drug-Drug Interaction Study of Digoxin and PA21
|
Phase 1 | |
| Completed |
NCT05558150 -
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac
|
Phase 1 | |
| Completed |
NCT03493698 -
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03126578 -
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
|
Phase 1 | |
| Completed |
NCT01369186 -
Drug Drug Interactions of Aspirin and P2Y12-inhibitors
|
Phase 4 | |
| Completed |
NCT02378220 -
Pharmacogenetic Testing Among Home Health Patients
|
N/A | |
| Completed |
NCT01324752 -
A Drug-Drug Interaction Study of Losartan and PA21
|
Phase 1 | |
| Completed |
NCT02500667 -
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT03801733 -
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
|
Phase 1 | |
| Completed |
NCT03801759 -
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
|
Phase 1 | |
| Completed |
NCT03801746 -
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
|
Phase 1 | |
| Completed |
NCT01736371 -
Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.
|
N/A |